Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer

Seasoned Industry Executive With More Than 20 Years of Oncology-Focused Drug Development Experience WALTHAM, Mass., June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage...
June 01, 2009 10:45 ET | Source: Oxigene, Inc.

OXiGENE Reports Positive Data From Phase 2 Trial of ZYBRESTAT in Platinum Resistant Ovarian Cancer At the 2009 ASCO Annual Meeting

Final Data Presentation Shows 25% Confirmed Response Rate in Relapsed Patient Population WALTHAM, Mass., June 1, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a...
May 21, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology

WALTHAM, Mass., May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
May 11, 2009 16:00 ET | Source: Oxigene, Inc.

OXiGENE Reports First Quarter 2009 Financial Results

WALTHAM, Mass., May 11, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
May 04, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Announces First Quarter 2009 Earnings Conference Call and Webcast

WALTHAM, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
April 22, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Reports Preclinical Data for OXi4503 Showing Pronounced Antitumor Activity in Animal Studies in Acute Myeloid Leukemia

OXiGENE Reports Preclinical Data for OXi4503 Showing Pronounced Antitumor Activity in Animal Studies in Acute Myeloid Leukemia At the American Association of Cancer Research Annual Meeting...
April 06, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular Disrupting Agent

OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular Disrupting Agent WALTHAM, Mass., April 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage...
March 30, 2009 16:00 ET | Source: Oxigene, Inc.

OXiGENE Receives Qualified Opinion On Its Audited Financial Statements for 2008

WALTHAM, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
March 19, 2009 16:00 ET | Source: Oxigene, Inc.

OXiGENE Reports Fourth Quarter and Year-End 2008 Results

WALTHAM, Mass., March 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
March 17, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Publication of Phase 2 Study Results With Fosbretabulin (ZYBRESTAT(tm)) Monotherapy in Anaplastic Thyroid Cancer (ATC)

WALTHAM, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...